DNDi is very pleased to announce the renewed commitment of the Global Health Innovative Technology Fund (GHIT), its donor since 2013, to DNDi projects on leishmaniasis and Chagas disease.
The new funding will support:
- a hit-to-lead collaboration between Daiichi Sankyo and DNDi in the areas of leishmaniasis and Chagas disease, through a grant of US$780,000. The project aims to progress promising hit series, all of which were previously identified through a GHIT-supported screening venture, into potential treatment leads for these diseases.
Read Daiichi Sankyo-DNDi press release
- the Neglected Tropical Diseases Drug Booster programme – an innovative initiative committed to accelerating early-stage drug discovery for treatments for leishmaniasis and Chagas disease, with a continued funding to DNDi, Eisai, Shionogi & Co. Ltd. (Japan) and Takeda Pharmaceutical Company Limited of US$550,000. This new investment will allow partners to continue the work of the Booster programme, which seeks to overcome early-stage intellectual property barriers and enable DNDi to search for new leads by evaluating thousands of unique compounds simultaneously.
- an effort to identify novel drug targets for a group of deadly parasitic diseases, notably Chagas disease and leishmaniasis, through a grant of US$980,000. This work will be led by the RIKEN Center for Sustainable Resource Science (Japan), the Structural Genomics Consortium at University of Toronto (Canada), the University of Melbourne (Australia), McGill University (Canada), the Medicines for Malaria Venture, and DNDi.
Read press releases on GHIT support to DNDi projects:
- GeneDesign-DNDi collaboration for cutaneous leishmaniasis
- Takeda-DNDi lead optimization collaboration for visceral leishmaniasis
- Launch of the NTD Drug Booster and financial support by GHIT
- Welcome of the GHIT launch and first grant to DNDi
Photo credit: Don Paul-DNDi